Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 44, Issue 3, Pages 688-692Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.44.3.688-692.2000
Keywords
-
Categories
Funding
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041690, U01AI032766, U01AI038858] Funding Source: NIH RePORTER
- NIAID NIH HHS [U01 AI038858, AI41690, AI38858, AI32766] Funding Source: Medline
Ask authors/readers for more resources
Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cyto megalovirus (CMV) cell-associated clinical isolates, Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two Isolates. Analysis of these results indicates the problems associated,vith clinical isolates, including the large genetic variability and the highly cell-associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available